BIOCHINA(EBC) originated from 2016, is the largest bio convention with a scale of more than 20,000 participants in China. Associating with scientific research, biotech and biopharma companies, government regulation agencies, and clinical institutions, the convention lined up each sector for advancing the bio ecosystem in China. The following licensing activities showcase our esteemed partners, who effectively represent the Chinese bio-industry in their global market endeavors.

Important Events of Internationalization of Innovative Drugs from January to August 2023 (Drugs distribution) Licensor Status Drug Target Indications Remarks BeiGene Has been approved for listing BRUKINSA® BTK MCL, CLL/SLL, etc It was first approved for listing by FDA in November 2019. US sales reach $390 million in 2022 Legend Biotech Carvykti BCMA CAR-T Recurrent and/or refractory multiple myeloma It was first approved for listing by FDA in February 2022, US sales hit $134 million in 2022 Hengrui In progress Karelizumab, Apatinib PD-1, VEGFR2 First-line hepatocellular carcinoma Submit the listing application in May 2023 BeiGene Tirelizumab PD-1 Squamous cell carcinoma of esophagus On-site verification in 2022 was affected by the epidemic, and progress is expected in 2023 Junshi biology Triprizumab PD-1 Recurrent or metastatic nasopharyngeal carcinoma On-site verification in 2022 was affected by the epidemic, and progress is expected in 2023 Yifan Pharmaceutical  F-627 Bergstine Long-acting G-CSF Neutropenia due to chemotherapy On-site verification in 2022 was affected by the epidemic, and progress is expected in 2023 HUTCHMED Furquintinib VEGFR etc Metastatic colorectal cancer In March 2023, the rolling submission of listing application was completed

Important Events of Internationalization of Innovative Drugs from January to August 2023 (Overseas Authorization) Licensor Licensee Project Transaction date Down payment Total transaction amount Authorized area Minhai Biotechnology Importer of Saudi Arabian medicine 13-valent pneumococcal polysaccharide conjugate Pneumococcal polysaccharide vaccine 2023/5/18 Undisclosed Undisclosed Undisclosed Li Xin Medicine AstraZeneca LM-305 2023/5/12 $55 million $600 million Global Junshi Biosciences Dr. Reddy's Laboratories Triprizumab 2023/5/5 $10 million $728.3 million Basilun, Root, Peru, Chile, Panama, Uruguay, India Cellular Biomedicine Group Janssen C-CAR039, C-CAR06 2023/5/2 $245 million Undisclosed Global (excluding China) Senlang biology Vaxcell Bio BCMA-CART products 2023/4/19 Undisclosed Undisclosed Korea GeneQuantum Healthcare Pyramid Biosciences GQ1010 2023/4/13 $20 million $1.02 billion Global (excluding Greater China) Chia Tai-Tianqing Pharmaceutical 、 Akeso STA Paianprizumab injection 2023/4/11 Undisclosed $73 million Australia, New Zealand, Papua New Zealand Asia, as well as Singapore, Malaysia and other southeast Minhai Biotechnology Biotis Pharmaceuticals Dual vector 13-valent pneumococcal polysaccharide 2023/4/6 Undisclosed Undisclosed Sub-11 countries Indonesia Duality Biologics BioNTech DB-1303 and DB-1311 2023/4/3 $170 million $1.67 billion Global (excluding Chinese mainland, Hong Kong and Macao) Gaoguang pharmaceutical Biohaven Pharmacout ica ls TLL-041 2023/3/22 $20 million $970 million Global (excluding Greater China) AnnJi Pharmaceutical Avenue Therapoutics AJ201 2023/3/2 $3 million Undisclosed The United States, the European Union, the United Kingdom, Canada, Israel Column Keymed Biosciences AstraZeneca CMG901 2023/2/23 $63 million $1.188 billion Global And platinum medicine Cullinan Oncology HBM7008 2023/2/14 $25 million $625 million United States (including the District of Columbia and Puerto Rico Each): EU or Australia (with the right) CSPC Pharmaceutical Group Corbus Pharmacouticals SYS6002 2023/2/13 $7.5 million $692.5 million The United States, European Union countries, Britain, Canada, Australia, Iceland, Liechtenstein, Norway And scholars Hengrui Treoline Biosciences SHR2554 2023/2/12 $11 million $650 million Global (excluding Greater China) Zhimeng Biopharma GlaxoSmithKline CB06 2023/2/2 Undisclosed Undisclosed Global HUTCHMED Takeda Biting quintinib 2023/1/23 $400 million $1.13 billion Global (excluding mainland China, Hong Kong and Macao) Mabwell Disc Medicine 9MW3011 2023/1/20 $10 million $412.5 million Global (excluding Greater China and Southeast Asia) Evopoint AmMax New generation ADC 2023/1/10 Undisclosed $871 million Global (excluding Greater China) Evopoint    METiS SOS1 inhibitor 2023/1/6 Undisclosed Hundreds of millions of dollars Global Duality Biologics Wuxi Biologics Adsendo GlaxoSmithKline ADC Platform "DITAC Several TCE antibodies in early detection stage 2023/01/05 2023/01/04 $40 million $1.5 billion Global

Register for BIOCHINA2024(EBC)   Follow us on Linkedin: Enmore Healthcare China Booth Enquiries +86-21-51550819 Cathyyuan@enmore.com Conference Enquiries +86-21-51550889 jessieyu@enmore.com